“The next bastion to be conquered in immunothera
Post# of 148110
(Total Views: 1043)
Posted On: 06/01/2024 8:46:46 AM
“The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer”
This journal reference reviewing the state of affairs with MSS CRC is from December 2023 and a pretty thorough review. Colon cancer is the second leading cause of cancer death worldwide…obviously a big market but also a big problem to solve. You can’t read this article and not walk away without the impression the medical community is throwing darts at it, typically with multiple agent regimens. Regorafenib from Merck is part of the salvage landscape; nivolumab (opdivo) and ipilimumab (yervoy) in combo, both Bristol Myers Squibb drugs, are also part of the salvage regimen landscape. Their R&D headquarters are in Redwood City, Dr. Lalezari’s neighborhood.
My other major impression after reading the journal article is that any palpable success with MSS CRC will turn heads and this would light a fire for Cytodyn and cast a major spotlight on LivImmune. Checkpoint inhibitors speak to 15% of colon cancer, the other 85% representing the core of the vast population inhabiting the second leading cause of cancer death are wandering in the treatment wilderness with scant hope. Small wonder Dr Lalezari is pivoting to MSS CRC. Success with this indication will be massive news!
Back to the clinic…unassailable results…
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770832/
This journal reference reviewing the state of affairs with MSS CRC is from December 2023 and a pretty thorough review. Colon cancer is the second leading cause of cancer death worldwide…obviously a big market but also a big problem to solve. You can’t read this article and not walk away without the impression the medical community is throwing darts at it, typically with multiple agent regimens. Regorafenib from Merck is part of the salvage landscape; nivolumab (opdivo) and ipilimumab (yervoy) in combo, both Bristol Myers Squibb drugs, are also part of the salvage regimen landscape. Their R&D headquarters are in Redwood City, Dr. Lalezari’s neighborhood.
My other major impression after reading the journal article is that any palpable success with MSS CRC will turn heads and this would light a fire for Cytodyn and cast a major spotlight on LivImmune. Checkpoint inhibitors speak to 15% of colon cancer, the other 85% representing the core of the vast population inhabiting the second leading cause of cancer death are wandering in the treatment wilderness with scant hope. Small wonder Dr Lalezari is pivoting to MSS CRC. Success with this indication will be massive news!
Back to the clinic…unassailable results…
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770832/
(19)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼